Member Info for liquid1

Proactive Investors Stocktube
Published on 24 May 2019
Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim.

Feedback from that meeting is expected in early June.

Motif's acknowledged additional data will likely be required to address the agency’s concern about a risk of liver toxicity, although it will wait to hear what the FDA has to say before deciding the size and scope of any potential study.

https://www.youtube.com/watch?v=p3HQzzZQhpI

3 scenarios possible!

Not long to RNS

Shares outstanding 460.75m
Free float 138.88m

https://markets.ft.com/data/equities/tearsheet/summary?s=NFX:LSE

Before the meeting:

• Work with RPM to establish agreeable agenda
and acceptable list of questions
• Notify RPM of any last minute changes (list of
attendees, audio/visual equipment)
– Foreign visitors
– Lobby Guard
• Provide the Division with any meeting hand-outs
and/or slides, if possible before the meeting
REdI Conference Meetings with CDER

--------------------------------------------------------------------------------------------
16
During the meeting:

• THIS IS YOUR MEETING
• Take the lead
– Make sure that your questions have been
addressed
– Summarize key discussion points,
agreements, and action items

https://www.fda.gov/media/91689/download

Motif Bio PLC ADR

PREMARKET
Last Updated: May 29, 2019 8:00 a.m. EDT
Delayed quote
$
2.16
0.06 2.86%
Before Hours Volume: 1000

SAND GROVE OPPORTUNITIES MASTER FUNDLDT

Sounds about right Doc. Motif was told more data was required on liver toxicity. Motif would definitely have taken liver specialists as you state to the minutes meeting to clarify any issues that FDA have! Just bloody common sense! Roll on RNS

https://www.**********.co.uk/articles/will-further-fda-discussions-lead-to-approval-for-motif-bio-s-antibiotic-iclaprim--5df57ba/ In a conference call to investors and analysts, Motif Bio confirmed that the FDA had no questions over the clinical efficacy of Iclaprim. However the FDA stated it needs additional data to further evaluate the risk for liver toxicity before the NDA approval.

What just happened? Motif Bio plc (NASDAQ:MTFB) stock value has climbed by nearly 14.21% or (0.26 points) to $2.09 from its previous close of $1.83. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 157311 contracts so far this session. MTFB shares had a relatively better volume day versus average trading capacity of 635.04 thousand shares, but with a 14.76 million float and a -3.17% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for MTFB stock indicates that the average analyst price target is $3.5 per share. This means the stock has a potential increase of 67.46% from where the MTFB share price has been trading recently which is between $1.79 and $1.94.

The shorts are running away from Motif Bio plc (MTFB) stock. The latest set of short interest data was released on 15 May 2019, and the numbers show a drop in short interest in MTFB shares. While short interest still represents only 0.55% of MTFB’s float, the number of shares shorted have fallen by -16792. The number of shares shorted fell to 51980 shares, down from 68772 shares during the preceding fortnight. With average daily trading volumes at 166424 shares, days to cover decreased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Motif Bio plc AGM Statement” and dated May 22, 2019.

https://www.findanews.com/2019/05/28/why-motif-bio-plc-mtfb-stock-was-rallying-today/amp/

30 days up on 31st May Let’s have the FDA minutes meeting RNS

In a conference call to investors and analysts, Motif Bio confirmed that the FDA had no questions over the clinical efficacy of Iclaprim. However the FDA stated it needs additional data to further evaluate the risk for liver toxicity before the NDA approval.

https://stocktwits.com/symbol/MTFB

Northland Securities Thinks Motif Bio plc’s Stock is Going to Recover

Catie Powers-May 22, 2019, 10:56 AM EDT SHARE ON:

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Motif Bio plc (MTFB), with a price target of $5. The company’s shares opened today at $1.78, close to its 52-week low of $1.54.

Byrnes said:

“We expect a clear view of the size and scope of a liver safety study after its receipt of minutes from the May 3rd Type A meeting. We anticipate an update in June. Motif also continues to expand targeted indications with recently announced agreements involving toxoplasmosis and CF-related lung infections indications.”

https://www.smarteranalyst.com/brief/northland-securities-thinks-motif-bio-plcs-stock-is-going-to-recover-3/?mod=mw_quote_news

Typo **

WTFDIK

Last time the word FDA came out Nasdaq took sp up to 14p!

No idea what the future holds, but I'm sure Motif answered their concerns regarding liver issues if any!!!

WTFDIK

Last time the word FDA came out Nasdaq tooth sp up to 14p!

No idea what the future holds, but I'm sure Motif answered their concerns regarding live issues if any!!!

mg

Trying to get in cheap!

News due this week from FDA will send this in upper double digits!

Was up 20% earlier!

FDA news this week on minutes meeting.

https://miningmaven.com/media/podcasts/861-miningmaven-podcast-106-with-craig-brown-of-ecr-minerals-ecr

MiningMaven Podcast 106 with Craig Brown of ECR Minerals (ECR)
In today's podcast we speak with Craig Brown, executive chairman of ECR Minerals (LSE:ECR). The company is mainly focussed on exploring for gold in the Victoria region of Australia, with a very active drilling campaign across a number of licenses. In this episode, Craig discusses recent drilling activities at the Creswick Gold Project, and the Blue Moon and Black Cat licenses.

10p with assay results would be awesome!